Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
pozelimab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
|
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (2023)) |
International Nonproprietary Names | |
INN number | INN |
10945 | pozelimab |
Synonyms |
pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 898 |
Other databases | |
GtoPdb PubChem SID | 485206021 |
Search PubMed clinical trials | pozelimab |
Search PubMed titles | pozelimab |
Search PubMed titles/abstracts | pozelimab |